Literature DB >> 22674623

Characterization of hepatic adenoma and focal nodular hyperplasia with gadoxetic acid.

Kiyarash Mohajer1, Alex Frydrychowicz, Jessica B Robbins, Agnes G Loeffler, Thomas D Reed, Scott B Reeder.   

Abstract

PURPOSE: To characterize imaging features of histologically proven hepatic adenoma (HA) as well as histologically and/or radiologically proven focal nodular hyperplasia (FNH) using delayed hepatobiliary MR imaging with 0.05 mmol/kg gadoxetic acid.
MATERIALS AND METHODS: Five patients with six HAs with histological correlation were retrospectively identified on liver MRI studies performed with gadoxetic acid, and T1-weighted imaging acquired during the delayed hepatobiliary phase. Additionally, 23 patients with 34 radiologically diagnosed FNH lesions (interpreted without consideration of delayed imaging) were identified, two of which also had histological confirmation. Signal intensity ratios relative to adjacent liver were measured on selected imaging sequences.
RESULTS: All six hepatic adenomas (100%), which had histological confirmation, demonstrated hypointensity relative to adjacent liver on delayed imaging. Furthermore, all of the FNH (including 34 radiologically proven, 2 of which were also histologically proven) were either hyperintense (23/34, 68%) or isointense (11/34, 32%) relative to the adjacent liver on delayed imaging. None of the FNHs were hypointense relative to liver.
CONCLUSION: Distinct imaging characteristics of HA versus FNH on delayed gadoxetic acid-enhanced MRI, with adenomas being hypointense and FNH being iso- or hyperintense on delayed imaging may improve specificity for characterization, and aid in the differentiation of these two lesions.
Copyright © 2012 Wiley Periodicals, Inc.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22674623      PMCID: PMC3670428          DOI: 10.1002/jmri.23701

Source DB:  PubMed          Journal:  J Magn Reson Imaging        ISSN: 1053-1807            Impact factor:   4.813


  27 in total

Review 1.  Malignant transformation of liver adenoma: an analysis of the literature.

Authors:  Olivier Farges; Safi Dokmak
Journal:  Dig Surg       Date:  2010-04-01       Impact factor: 2.588

2.  Focal nodular hyperplasia and hepatic adenoma: epidemiology and pathology.

Authors:  Lucas Maillette de Buy Wenniger; Valeska Terpstra; Ulrich Beuers
Journal:  Dig Surg       Date:  2010-04-01       Impact factor: 2.588

3.  MRI of hepatic adenomatosis: initial observations with gadoxetic acid contrast agent in three patients.

Authors:  Olivier Giovanoli; Markus Heim; Luigi Terracciano; Georg Bongartz; Hans P Ledermann
Journal:  AJR Am J Roentgenol       Date:  2008-05       Impact factor: 3.959

4.  Liver vessel enhancement by Gd-BOPTA and Gd-EOB-DTPA: a comparison in healthy volunteers.

Authors:  T B Brismar; N Dahlstrom; N Edsborg; A Persson; O Smedby; N Albiin
Journal:  Acta Radiol       Date:  2009-09       Impact factor: 1.990

5.  Focal nodular hyperplasia: central scar enhancement pattern using Gadoxetate Disodium.

Authors:  Adib R Karam; Sridhar Shankar; Padmaja Surapaneni; Young H Kim; Sarwat Hussain
Journal:  J Magn Reson Imaging       Date:  2010-08       Impact factor: 4.813

6.  Gadoxetate disodium-enhanced hepatic MRI: dose-dependent contrast dynamics of hepatic parenchyma and portal vein.

Authors:  Sebastian Feuerlein; Daniel T Boll; Rajan T Gupta; Kristina I Ringe; Daniele Marin; Elmar M Merkle
Journal:  AJR Am J Roentgenol       Date:  2011-01       Impact factor: 3.959

7.  Double-dose gadoxetic Acid-enhanced magnetic resonance imaging in patients with chronic liver disease.

Authors:  Utaroh Motosugi; Tomoaki Ichikawa; Katsuhiro Sano; Hironobu Sou; Kojiro Onohara; Ali Muhi; Takatoshi Kitamura; Fumitake Amemiya; Nobuyuki Enomoto; Masanori Matsuda; Masami Asakawa; Hideki Fujii; Tsutomu Araki
Journal:  Invest Radiol       Date:  2011-02       Impact factor: 6.016

8.  Hepatocellular carcinoma: signal intensity at gadoxetic acid-enhanced MR Imaging--correlation with molecular transporters and histopathologic features.

Authors:  Azusa Kitao; Yoh Zen; Osamu Matsui; Toshifumi Gabata; Satoshi Kobayashi; Wataru Koda; Kazuto Kozaka; Norihide Yoneda; Tatsuya Yamashita; Shuichi Kaneko; Yasuni Nakanuma
Journal:  Radiology       Date:  2010-07-27       Impact factor: 11.105

9.  Diagnostic performance and description of morphological features of focal nodular hyperplasia in Gd-EOB-DTPA-enhanced liver magnetic resonance imaging: results of a multicenter trial.

Authors:  Christoph J Zech; Luigi Grazioli; Josy Breuer; Maximilian F Reiser; Stefan O Schoenberg
Journal:  Invest Radiol       Date:  2008-07       Impact factor: 6.016

10.  Enhancement of liver parenchyma after injection of hepatocyte-specific MRI contrast media: a comparison of gadoxetic acid and gadobenate dimeglumine.

Authors:  Antonella Filippone; Anthony Blakeborough; Josy Breuer; Luigi Grazioli; Simone Gschwend; Renate Hammerstingl; Gertraud Heinz-Peer; Thomas Kittner; Andrea Laghi; Edward Leen; Riccardo Lencioni; Olivier Lucidarme; Philipp Remplik; Philip J Robinson; Stefan G Ruehm; Fritz Schaefer; Christoforos Stoupis; Bernd Tombach; Pierre-Jean Valette; Christoph J Zech; Alexander Huppertz
Journal:  J Magn Reson Imaging       Date:  2010-02       Impact factor: 4.813

View more
  25 in total

1.  Gadoxetic acid enhanced MRI for differentiation of FNH and HCA: a single centre experience.

Authors:  Christian Grieser; Ingo G Steffen; Incken-Birthe Kramme; Hendrik Bläker; Ergin Kilic; Carmen Maria Perez Fernandez; Daniel Seehofer; Eckart Schott; Bernd Hamm; Timm Denecke
Journal:  Eur Radiol       Date:  2014-06       Impact factor: 5.315

Review 2.  Focal liver lesions detection and characterization: The advantages of gadoxetic acid-enhanced liver MRI.

Authors:  Stefano Palmucci
Journal:  World J Hepatol       Date:  2014-07-27

3.  Doughnut-like hyperintense nodules on hepatobiliary phase without arterial-phase hyperenhancement in cirrhotic liver: imaging and clinicopathological features.

Authors:  Kazuto Kozaka; Satoshi Kobayashi; Norihide Yoneda; Azusa Kitao; Kotaro Yoshida; Dai Inoue; Takahiro Ogi; Wataru Koda; Yasunori Sato; Toshifumi Gabata; Osamu Matsui
Journal:  Eur Radiol       Date:  2019-07-05       Impact factor: 5.315

4.  Tumor Contrast Enhancement and Whole-Body Elimination of the Manganese-Based Magnetic Resonance Imaging Contrast Agent Mn-PyC3A.

Authors:  Derek J Erstad; Ian A Ramsay; Veronica Clavijo Jordan; Mozhdeh Sojoodi; Bryan C Fuchs; Kenneth K Tanabe; Peter Caravan; Eric M Gale
Journal:  Invest Radiol       Date:  2019-11       Impact factor: 6.016

Review 5.  Patterns of enhancement in the hepatobiliary phase of gadoxetic acid-enhanced MRI.

Authors:  Cathryn L Hui; Marcela Mautone
Journal:  Br J Radiol       Date:  2020-06-01       Impact factor: 3.039

6.  Intravoxel incoherent motion and dynamic contrast-enhanced MRI for differentiation between hepatocellular adenoma and focal nodular hyperplasia.

Authors:  Naim Jerjir; Luk Bruyneel; Marc Haspeslagh; Sarah Quenet; Kenneth Coenegrachts
Journal:  Br J Radiol       Date:  2017-06-07       Impact factor: 3.039

7.  Optimal timing and diagnostic adequacy of hepatocyte phase imaging with gadoxetate-enhanced liver MRI.

Authors:  Mustafa R Bashir; Steven R Breault; Ryan Braun; Richard K Do; Rendon C Nelson; Scott B Reeder
Journal:  Acad Radiol       Date:  2014-04-06       Impact factor: 3.173

Review 8.  The diagnostic value of Gd-EOB-DTPA-MRI for the diagnosis of focal nodular hyperplasia: a systematic review and meta-analysis.

Authors:  Chong Hyun Suh; Kyung Won Kim; Gene Young Kim; Yong Moon Shin; Pyo Nyun Kim; Seong Ho Park
Journal:  Eur Radiol       Date:  2014-12-24       Impact factor: 5.315

9.  A cost-effectiveness analysis of the diagnostic strategies for differentiating focal nodular hyperplasia from hepatocellular adenoma.

Authors:  Chong Hyun Suh; Kyung Won Kim; Seong Ho Park; Sangjin Shin; Jeonghoon Ahn; Junhee Pyo; Atul B Shinagare; Katherine M Krajewski; Nikhil H Ramaiya
Journal:  Eur Radiol       Date:  2017-07-19       Impact factor: 5.315

10.  Focal nodular hyperplasia: characterisation at gadoxetic acid-enhanced MRI and diffusion-weighted MRI.

Authors:  H S An; H S Park; Y J Kim; S I Jung; H J Jeon
Journal:  Br J Radiol       Date:  2013-07-19       Impact factor: 3.039

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.